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Abstract:  
Frailty, a clinical syndrome that typically occurs in older adults, implies a reduced ability 
to tolerate biological stressors. Frailty accompanies many age-related diseases but can 
also occur without overt evidence of end-organ disease. The condition is associated with 
circulating inflammatory cytokines and sarcopenia, features that are shared with heart 
failure (HF).  However, the biological underpinnings of frailty remain unclear and the 
interaction with HF is complex. Here, we describe the inflammatory pathophysiology 
that is associated with frailty and speculate that the inflammation that occurs with 
frailty shares common origins with HF.  We discuss the limitations in investigating the 
pathophysiology of frailty due to few relevant experimental models. Leveraging current 
therapies for advanced HF and current known therapies to address frailty in humans 
may enable translational studies to better understand the inflammatory interactions 
between frailty and HF.  
 
Introduction  
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As the number of people over 65 year of age grows, so too will the rate of 
cardiovascular diseases in the population. This growth will pose an increasing burden on 
our health care system and resources, particularly as cardiovascular disease in older 
people overshadows all other age-related end-organ diseases including infectious 
diseases, cancer, and lung diseases. There is thus an urgent need to understand how 
aging impacts cardiovascular diseases. Among cardiovascular diseases in older people, 
heart failure (HF) is a major cause of morbidity and mortality. Importantly, people over 
65 years of age constitute >80% of patients with HF and the incidence of HF is 10 per 
1000 in people aged > 65 years of age (Go et al. 2013).  
Approximately 25% of older patients with HF exhibit evidence of frailty, a clinical 
syndrome characterized by reduced tolerance to biological stressors (Boxer et al. 2008; 
Dodson & Chaudhry 2012). Frailty can also occur independently of HF, although both 
frailty and HF are associated with a proinflammatory phenotype. It was recently 
demonstrated that of several organ systems, frailty is most highly associated with 
cardiovascular dysfunction(Nadruz et al. 2016). In this review, we speculate that HF and 
frailty may be linked via a common inflammatory pathway and describe how this 
inflammation may be initiated. We discuss our limitations in understanding the 
underlying pathophysiology of frailty posed by current confines in experimental models 
of frailty in contrast to HF (Patten & Hall-Porter 2009)  
 
Definition of Frailty:  
Frailty is a state of excess vulnerability to biological stressors due to a decline in 
functional reserve across multiple physiologic systems with a resultant inability to 
maintain homeostasis at baseline or regain homeostasis after a destabilizing event (Xue 
2011). While there is no universally accepted method of assessing frailty, some of the 
commonly used tools include individual metrics of unintentional weight loss, fatigue, 
low physical function and strength such as gait speed and handgrip strength (Ling et al. 
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2010), and presence of comorbidities. Comprehensive scales such as the Fried index, 
Rockwood index, and Short Physical Performance Battery (SPPB) are also commonly 
used (Dodson & Chaudhry 2012; (Flint et al. 2012) (Afilalo et al. 2009; Morley et al. 
2013; Afilalo et al. 2014), described in detail elsewhere ((Fried et al. 2001; Morley et al. 
2013; Chamberlain et al. 2016). Together, these serve to limit mobility, independence, 
and the ability to perform activities of daily living in older adults (Chamberlain et al. 
2016). In this review, we describe the underlying inflammatory phenotype associated 
with frailty and speculate how it may be linked to the inflammatory phenotype that 
occurs with HF.  
Whether frailty is an independent process or the result of a culmination of various 
comorbidities that occur with aging is an ongoing debate. Epidemiological data from the 
Cardiovascular Health Study suggests that 15% of pre-frail and 7% of frail patients do 
not exhibit comorbid conditions (Fried et al. 2001). This finding supports the concept 
that frailty and other diseases are independent conditions. It is also possible that there 
may be two forms of frailty, one associated with aging and resultant sarcopenia and 
anorexia but without evidence of end-organ disease, and the other more common form, 
which occurs in the setting of comorbidities or severe illnesses (Fried et al. 2001).  
End organ disease such as HF exacerbates frailty. It is unclear, however, if frailty itself 
can contribute to organ dysfunction and resultant HF. Results from the Health, Aging 
and Body Composition Study found that in community dwelling individuals, moderate 
and severe frailty have an increased risk of incident heart failure diagnosis (Khan et al. 
2013).  While there is no direct relationship between frailty and severity of HF, there is 
evidence that frailty is more common with acute decompensated heart failure (ADHF) as 
compared to those with chronic stable preserved ejection fraction (HFpEF) and reduced 
ejection fraction (HFrEF) (Reeves et al. 2016). More than half of the patients admitted 
with ADHF were found to be frail. This state is promoted by chronic underlying skeletal 
muscle changes from long standing heart failure, but an acute myopathic process can 
also develop during hospitalization and be compounded by immobility.(Puthucheary et 
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al. 2013; Kitzman et al. 2014).  Our lack of understanding of the etiology and the 
implications of frailty are due to our poor comprehension of the pathophysiology of this 
condition. Frailty and HF are both associated with inflammation (Fedarko 2011), thus 
gaining a better understanding of how inflammation occurs may reveal how frailty 
develops and how it relates to HF.  
Overview of the pathophysiology of inflammation 
Innate immune signaling 
The induction of inflammation is a host defense mechanism evolved to alert the 
immune system and limit microbial invasion. Inflammation is typically induced when the 
innate immune system, which acts as the first line of defense to infection (Medzhitov & 
Janeway 2000), is activated. The toll like receptors (TLR) are membrane bound innate 
immune receptors that respond to microbial components, for example cell surface 
bound TLR4 is activated by lipopolysaccharide, and TLR9 expressed within endosomes is 
activated by unmethylated CpG DNA sequences (reviewed in (Takeuchi & Akira 2010). 
Activation of TLRs leads to the translocation of NF-kB, a key intra-cellular controller of 
inflammation, leading to the production of inflammatory cytokines (e.g. IL-6 and TNF฀) 
and the upregulation of costimulatory molecules on dendritic cells and macrophages, 
key innate sentinel immune cells (Shirali & Goldstein 2008). In addition to membrane 
bound innate immune receptors, intracellular innate immune pathways include the 
inflammasome, a multi-protein complex that is activated by Nod like receptors (NLR) 
which leads to the production of IL-1β฀฀(Chen & Nunez 2010). The inflammasome is 
known to be activated by bacteria (e.g., salmonella) and viruses (e.g., influenza) 
(Lamkanfi & Dixit 2014) The RIG-I like receptors (RLR) respond to intracellular nucleic 
acids in the context of viral infections (e.g., influenza virus) to produce type 1 
interferons (IFN) (Yoneyama et al. 2015).  
 
Sterile Inflammation  
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
The TLRs and inflammasome pathways are activated by host derived proteins in addition 
to microbial motifs leading to sterile inflammation, which is defined as inflammation 
without microbes (Shen et al. 2013). Sterile inflammation occurs in conditions such as 
acute ischemia reperfusion injury or during chronic inflammatory processes evident 
with HF (Shen et al. 2013). Chronic inflammatory markers are also associated with frailty 
(Darvin et al. 2014). Sterile inflammation occurs when cellular necrosis leads to the 
release of host substances that typically do not activate the innate immune system. For 
example the release of mitochondrial DNA that activates Toll-like receptor (TLR) 9 
induces myocardial inflammation and HF (Oka et al. 2012) Free mitochondrial DNA in 
plasma can also activate TLR5 and the NLR-induced inflammasome. (Zhang et al. 2010; 
Dall'Olio et al. 2013). Sterile and microbial inflammation can act simultaneously as 
exemplified by HF when reduced gut perfusion compromises epithelial surfaces and 
leads to gut commensal bacteria translocating into the portal circulation. Once in the 
portal circulation these bacteria active innate immune receptors, such as TLRs, to induce 
inflammation.  
Whether the initial stimulus is microbial, sterile or a combination of both, persistent 
innate immune activation leads to chronic inflammation, which can manifest as 
increased levels of circulating levels of pro-inflammatory cytokines such as TNFα, IL-6 
and IFN-γ, and proteins such as C reactive protein, (CRP). Importantly, the induction of 
inflammation leads to negative feedback pathways to resolve inflammation, via immune 
suppressive cytokines like IL-10 or resolvins (Serhan et al. 2008). These mediators 
enhance the clearance of dying neutrophils by macrophages, a process termed 
efferocytosis (Greenlee-Wacker 2016). Hence, chronic inflammation can occur either by 
persistent activation or a failure to resolve inflammation.  
Aging in humans has been associated with increased, low levels of circulating pro- 
inflammatory cytokines (Tracy 2003; De Martinis et al. 2006).Even in reportedly healthy 
older humans, there is evidence for an increase in circulating inflammatory proteins. 
The precipitants of chronic, low-grade inflammation with aging could be sterile or 
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microbial. Sterile inflammation may result from the breakdown of tissues such as 
adipose, skeletal muscle, or cardiomyocytes, whereas chronic, indolent viral infections 
(e.g. cytomegalovirus) can also lead to chronic inflammation. This may be exacerbated 
in HF as increased intra-vascular pressure may result in intestinal congestion, abdominal 
discomfort, and appetite loss which may lead to cachexia (Valentova et al. 2016). Frailty 
is associated with increased circulating of TNFα, IL-6, IFN-γ, and CRP and these 
mediators are also elevated in HF patients (Kalogeropoulos et al. 2010; Mann 2015). 
This suggests that there could be shared inflammatory pathways that are activated by 
HF and frailty, as discussed below. In support of the inflammatory pathophysiology of 
frailty, a recent study found that nonagenarians, but not humans under 30 years of age, 
exhibit a significant correlation between plasma levels of cell- free DNA, a known 
activator of TLR9 and elevated levels of IL-6 and CRP (Jylhava et al. 2013). Importantly, 
this study correlated levels of plasma DNA with frailty in the older patient cohort.  
How aging, frailty and HF interact to induce inflammation  
How aging occurs remains unclear (Gladyshev 2016). Current theories include: genetic 
programing, mutation accumulation, antagonistic pleiotropy (a process in which genes 
that are beneficial for reproductive fitness become detrimental as an organism ages), 
and accumulation of damaged proteins (Gladyshev 2016). Whatever the actual cause of 
biological aging, aging is associated with several detrimental processes including DNA 
damage, impaired autophagy (a cell biological process important for clearance of 
damaged organelles (Martinez-Lopez et al. 2015) and elevated oxidative stress due to 
mitochondrial dysfunction (Fridovich 2004) (Wang & Bennett 2012)Tchkonia et al. 
2013;(Palmer et al. 2015). Interestingly, HF is associated with similar cellular 
perturbations, which suggests that HF could be considered as an accelerated form of 
aging (Dutta et al. 2012; Wohlgemuth et al. 2014). Thus, it is possible that the processes 
that underlie both frailty and HF could each perturb homeostasis to lead to low-level 
chronic inflammation.  
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The etiology of inflammation that leads to frailty may be shared or independent to HF. It 
is likely that HF leads to frailty but whether frailty that precedes HF causes cardiac 
dysfunction is not clear (Figure 1). DNA damage, impaired autophagy, and mitochondrial 
dysfunction are biological processes that occur in both aging and HF and these 
processes can lead to metabolic dysfunction, cellular senescence, and ultimately cellular 
necrosis, leading to activation of innate immunity and the production of inflammatory 
mediators into the circulation. The protein STAT3 limits redox stress and promotes  
mitochondrial function, and mice lacking STAT3 have increased proinflammatory 
cytokines and cardiac fibrosis with age (Jacoby et al. 2003).  Additionally, senescence-
prone mice have elevated levels of pro-inflammatory cytokines including IL-1β, a 
signature cytokine of inflammasome activation (Saito & Papaconstantinou 2001; 
Karuppagounder et al. 2016).  Aged mice (24 months of age) deficient in the NLRP3 
inflammasome exhibit enhanced walk distance and running time as compared to their 
wild type controls, suggesting that NLRP3 may enhance inflammation that leads to 
frailty (Youm et al. 2013). Interestingly, there is emerging evidence of NLRP3 activation 
in HF patients (Butts et al. 2015). Hence, the NLRP3 inflammasome may be a common 
pathway by which frailty and HF interact, although definitive proof will require future 
investigation. 
  Dysregulated mitophagy also fails to maintain a pool of high quality mitochondria, the 
mitochondrial oxidative phosphorylation and membrane potential per mitochondrion 
increases to meet cellular demand (Twig & Shirihai 2011). This leads to greater 
production of ROS and damage to mitochondrial proteins, lipids, and DNA which further 
activates innate immunity and chronic inflammation (Baroja-Mazo et al. 2014; Wu et al. 
2015).  These processes contribute to cardiomyocyte dysfunction, which occurs with 
aging and could, in turn, lead to chronic inflammation, remodeling within the 
myocardium, and pathological left ventricular hypertrophy to exacerbate HF regardless 
of etiology (Tsutsui et al. 2009; Hafner et al. 2010; Hoshino et al. 2013).  As aging is 
linked to both frailty and HF, it is conceptually plausible that the impaired biological 
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processes that lead to chronic inflammation serve as a common pathophysiological link 
between frailty and HF (Figure 1).  
As cells die they release intracellular contents, such as DNA that activate inflammation. 
An experimental study found that defects in clearing defective mitochondria (i.e., a 
process termed mitophagy (Lemasters 2005)) within the myocardium, leads to 
mitochondrial dysfunction (Hoshino et al. 2013). Furthermore, defective mitophagy 
within the myocardium leads to cell death and the release of mitochondrial DNA that 
activates Toll-like receptor (TLR) 9 to induce myocardial inflammation, pressure 
overload, and cardiac hypertrophy leading to HF (Oka et al. 2012). Defective mitophagy 
also leads to accumulation of dysfunctional mitochondria which produce more 
proinflammatory signals, termed mitochondrial damage-associated molecular patterns 
(Zhang et al. 2010; Dall'Olio et al. 2013). Skeletal muscle from older adults has reduced 
ATP production, maximal bioenergetic capacity, and mitochondrial content compared to 
younger counterparts (Short et al. 2005) and cardiac muscle oxidative phosphorylation 
capacity is reduced in the earliest stages of heart failure in humans (Diamant et al. 2003; 
Hepple 2016). Skeletal muscle oxidative capacity, mitochondrial content and fusion are 
abnormal in older patients with HFpEF (Molina et al. 2016). Thus, a potential unifying 
model for a common pathophysiological pathway between frailty and HF may be 
impaired mitophagy and mitochondrial dysfunction within cardiomyocytes and skeletal 
muscle, causing cell death and activation of innate immunity to induce chronic, low 
grade systemic inflammation.  
As HF may enhance frailty, another model for the interaction between HF and frailty is 
that HF precedes or exacerbates frailty. The hemodynamic alterations that occur with 
HF could induce tissue hypoxia, with resulting cell death and inflammation (Figure 1). 
Furthermore, intestinal ischemia from poor gut perfusion and/or congestion related to 
volume overload, as discussed above, could lead to translocation of gut bacterial 
commensals, which could activate innate immunity to heighten systemic inflammation 
and increase risk for HF (Rogler & Rosano 2014). Finally, neurohormonal pathways, such 
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as the renin-angiotensin system via activation of the sympathetic nervous system, which 
is induced by HF can also activate innate immunity (Mann 2015) to induce low grade 
sterile inflammation (Kalra et al. 2002).  
As frailty can occur without end stage disease, HF is not required for frailty as stated 
above. Whether frailty mechanistically leads to end-organ disease such as HF is not 
known (Figure 1). It is also plausible that the chronic inflammation that occurs with 
frailty has a distinct origin from that of HF. One can speculate that cellular senescence in 
extra- cardiac sites, such as adipose tissue, lymphoid system or the vasculature, may 
lead to chronic inflammation. The subsequent inflammation could lead to frailty and 
could also negatively effect myocardial function “from a distance” via the negative 
inotropic effects of the circulating cytokines (Mann 2015). Interestingly, chronic 
inflammation and associated vascular dysfunction have also recently been linked to 
HFpEF (Paulus & Tschope 2013; Glezeva et al. 2015; Franssen et al. 2016), the most 
common form of HF in the older adults (Upadhya et al. 2015). Systemic inflammation 
can also accelerate skeletal muscle apoptosis, and promote sarcopenia (Muscaritoli et 
al. 2010). Conceivably, this could enhance immobility and cachexia associated with both 
HF and frailty. Clearly future research will be required to decipher the role inflammation 
plays in the complex interaction between HF, frailty and cachexia (Hubbard et al. 2008).  
How to examine the mechanisms of frailty experimentally  
One of the challenges in delineating the underlying pathophysiology of frailty is that, 
unlike HF (Patten & Hall-Porter 2009), there are limited experimental models to 
investigate the pathophysiology of frailty, at least frailty that is not accompanied by end-
organ disease. Development of such models would allow one to elucidate the etiology 
of elevated inflammatory proteins that occur with frailty and determine if the 
underlying pathophysiology of frailty is unique or shared with the pathophysiology of 
end-organ disease such as HF. It may also allow one to determine if an inflammatory 
mediator is causal to frailty or merely a result of frailty. Cause-effect relationship will be 
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important, given the result of clinical studies that found that inhibiting certain 
inflammatory cytokines, e.g. TNF-α, had no impact on mortality in the setting of HFrEF 
(Coletta et al. 2002). Investigators have found that mice that are deficient in IL-10, an 
immune suppressive cytokine, exhibit some clinical features of frailty, specifically 
declining muscle strength by 14 months of age as compared to age-matched wild type 
controls (Walston et al. 2008). This study represents a potential murine model of frailty 
however it is confounded as IL-10 deficient mice exhibit signs of inflammatory bowel 
disease (Davidson et al. 2000), which could explain the features described in the study. 
Recently a frailty index in aging wild type C57BL/6 strain mice has been developed by 
measuring 31 health related variables including mobility, hemodynamic, metabolic and 
body composition parameters both invasively (Parks et al. 2012) and more recently with 
non-invasive approaches (Whitehead et al. 2014) Furthermore, others have robustly 
characterized physical function measures in mice to standardize measures which could 
provide index values for physical function to aide in establishing murine models of frailty 
(Justice et al. 2014).  If measurements of chronic inflammation can be accurately 
assessed in wild type aging mice and correlated with this frailty assessment, then it may 
be possible to develop an experimental model to mechanistically investigate the 
inflammatory pathophysiological basis of frailty.  
Leveraging therapies for HF-a potential opportunity to inform of the biology of frailty 
and HF? 
There is accumulating evidence that endurance and resistance exercise training 
improves functional capacity and reduces hospitalizations in HF patients. (Gillespie et al. 
2012; Kitzman et al. 2016). The Heart Failure: A Controlled Trial Investigating Outcomes 
of Exercise Training (HF-ACTION) trial demonstrated favorable outcomes in patients 
with HFrEF although the effects of exercise training on formal measures of frailty and 
markers of inflammation were not studied in HF-ACTION(O'Connor et al. 2009). One 
potential mechanism of benefit with exercise training is reduction of inflammation 
within skeletal muscle (Addison et al. 2012) and importantly a prior study found that 
exercise training reduced local inflammation within the skeletal muscle (manifest by 
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iNOS protein levels) in patients with HFrEF (Gielen et al. 2005). Another recent study 
found that in patients with HFpEF there was a reduction in mitochondrial content within 
the skeletal muscle (Molina et al. 2016b), although this study did not correlate this to 
inflammation. It was shown that exercise-induced increase in cardiorespiratory fitness 
was associated with reductions in CRP in patients with HFpEF (Kitzman et al. 2016). It 
will thus be important for future investigation to determine whether improvements in 
frailty with exercise training correlate with reduction in either local inflammation within 
the skeletal muscle or systemic inflammation within the circulation.  
Currently, there are ongoing clinical studies to assess whether advanced therapies for 
HF (e.g., left ventricular assist device [LVAD] implantation) improves frailty symptoms 
(clinicaltrials.gov NCT02156583) or whether improving frailty symptoms prior to 
resolving the hemodynamics of HF improve outcomes after transcatheter aortic valve 
replacement (TAVR) (clinicaltrials.gov, NCT02597985). Few studies have examined if 
LVAD impact inflammatory cytokine levels, with one revealing that LVADs may reduce 
circulating IL-6 and TNFα levels one month after implantation (Clark et al. 2001)but 
another showing that CRP and IL-8 (a neutrophil attracting chemokine) increase post 
implantation (Grosman-Rimon et al. 2014). Interestingly, even medical management of 
acute decompensated HF can reduce innate immune activation (Goonewardena et al. 
2015). The relationship between alterations in cytokines post-LVAD implantation or 
acute treatment of decompensated HF and frailty has not yet been investigated and 
should be the focus of future investigation.  
As increasing numbers of older frail patients receive advanced options for end-stage HF, 
there is a unique opportunity to perform translational research that could inform on the 
inflammatory biological basis of frailty and how it interacts with HF. LVADs improve 
cardiac hemodynamics to resolve the poor tissue perfusion that occurs with HF. Thus 
investigation of frail patients with HF that receive LVADs could inform on the 
contribution of end organ dysfunction to the frailty clinical and inflammatory 
phenotypes. Future clinical investigation is required to determine if resolving the 
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hemodynamic alterations of HF using advanced therapeutic options would improve the 
systemic inflammatory profile associated with both frailty and HF.  
Given the anticipated rise in the number of older people with HF and current limited 
experimental models of frailty, there is a rare opportunity to leverage ongoing clinical 
practice to yield novel insights as to whether therapies that improve HF resolve the 
chronic inflammation that occurs in frailty and HF. Such lines of investigation could 
provide precious information on the biological underpinnings of frailty and end organ 
disease such as HF.  
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Figure Legend 
Figure 1 Possible inflammatory pathophysiological link between frailty and HF Processes that occur with 
aging, (e.g., cellular senescence, increased oxidative stress, reduced autophagy or mitophagy, increased 
DNA damage or mitochondrial dysfunction) accompany both frailty and HF. These processes may 
disrupt cellular homeostasis and lead to cell death. Cell death activates the innate immune system to 
induce inflammation manifest as circulating inflammatory cytokines. Subsequent inflammation may 
then exacerbate the cellular processes mentioned above to perpetuate cell death, in a positive 
feedback loop. HF may also exacerbate chronic inflammation independently of the above processes, by 
hemodynamic compromise, activation of the renin-angiotensin system, and translocation of gut 
bacterial commensals into the systemic circulation. HF likely induces frailty symptoms but it is less clear 
if frailty predisposes to HF. 
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